Patent 11408095 was granted and assigned to Merus on August, 2022 by the United States Patent and Trademark Office.
Provided are methods for efficiently and comprehensively screening antibody repertoires from B cells to obtain and produce molecules with binding characteristics and functional activities for use in human therapy.